INVA

Innoviva, Inc. focuses on maximizing the value of royalty streams from respiratory products co-developed with and licensed to GSK. The company engages in capital allocation strategies to deploy cash flows into areas of high unmet medical need, aiming to create long-term value for shareholders and improve patient outcomes. Innoviva has expanded its portfolio through strategic acquisitions and investments in therapeutic companies, including Entasis Therapeutics and La Jolla Pharmaceutical Company.